Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR1 | P21453 | 6/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | UBE2M | P61081 | 2/20 | 0.38 |
| ▸ | DCUN1D1 | Q96GG9 | 2/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.36 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.35 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.35 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.35 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.35 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4268235 | 0.90 | UBE2M (0.43) | S1PR1KDM4EGAAUBE2MDCUN1D1 | |
| SCHEMBL4276066 | 0.85 | HTT (0.38) | S1PR1KDM4EGAAUBE2MDCUN1D1 | |
| SCHEMBL4276074 | 0.85 | S1PR1 (0.43) | S1PR1KDM4EGAAUBE2MDCUN1D1 | |
| SCHEMBL4275089 | 0.84 | S1PR1 (0.35) | S1PR1KDM4EGAAUBE2MDCUN1D1 | |
| SCHEMBL4278854 | 0.83 | PTGIR (0.41) | S1PR1KDM4EGAAUBE2MDCUN1D1 | |
| SCHEMBL4273069 | 0.82 | S1PR1 (0.42) | S1PR1KDM4EGAAUBE2MDCUN1D1 | |
| SCHEMBL4269443 | 0.79 | UBE2M (0.42) | KDM4EGAAUBE2MDCUN1D1HTT | |
| SCHEMBL4268261 | 0.79 | UBE2M (0.43) | S1PR1KDM4EGAAUBE2MDCUN1D1 | |
| SCHEMBL4268265 | 0.79 | UBE2M (0.43) | S1PR1KDM4EGAAUBE2MDCUN1D1 | |
| SCHEMBL4272591 | 0.78 | S1PR1 (0.39) | S1PR1KDM4EGAAUBE2MDCUN1D1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7608739-B2 | Mitotic kinesin inhibitors | MERCK & CO. INC. (US) | 2009-10-27 | — | — | US | claimed |
| US-20080234281-A1 | Mitotic Kinesin Inhibitors | MERCK SHARP & DOHME CORP. | 2008-09-25 | — | — | US | claimed |
| EP-1730099-A4 | MITOTIC KINESIN INHIBITORS | MERCK & CO INC (US) | 2008-03-12 | — | — | EP | claimed |
| EP-1730099-A2 | MITOTIC KINESIN INHIBITORS | Merck & Co., Inc. (US) | 2006-12-13 | — | — | EP | claimed |
| WO-2005092011-A2 | MITOTIC KINESIN INHIBITORS | MERCK & CO., INC. (US) | 2005-10-06 | — | — | WO | claimed |
| US-7608739-B2 | Mitotic kinesin inhibitors | MERCK & CO. INC. (US) | 2009-10-27 | — | — | US | disclosed |
| US-7608739-B2 | Mitotic kinesin inhibitors | MERCK & CO. INC. (US) | 2009-10-27 | — | — | US | disclosed |
| US-7608739-B2 | Mitotic kinesin inhibitors | MERCK & CO. INC. (US) | 2009-10-27 | — | — | US | disclosed |
| US-20080234281-A1 | Mitotic Kinesin Inhibitors | MERCK SHARP & DOHME CORP. | 2008-09-25 | — | — | US | disclosed |
| US-20080234281-A1 | Mitotic Kinesin Inhibitors | MERCK SHARP & DOHME CORP. | 2008-09-25 | — | — | US | disclosed |
| US-20080234281-A1 | Mitotic Kinesin Inhibitors | MERCK SHARP & DOHME CORP. | 2008-09-25 | — | — | US | disclosed |
| EP-1730099-A4 | MITOTIC KINESIN INHIBITORS | MERCK & CO INC (US) | 2008-03-12 | — | — | EP | disclosed |
| EP-1730099-A2 | MITOTIC KINESIN INHIBITORS | Merck & Co., Inc. (US) | 2006-12-13 | — | — | EP | disclosed |
| WO-2005092011-A2 | MITOTIC KINESIN INHIBITORS | MERCK & CO., INC. (US) | 2005-10-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080234281-A1 | Mitotic Kinesin Inhibitors | KIF5B, KIF2C, KIF18B | S1PR1 2636/4885KDM4E 525/4885GAA 768/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.